ALK-Rearranged Non-Small Cell Lung Cancer Presenting as a Large Mediastinal Mass: A Case Report

被引：0
|
作者：
Weber, Urs M. [1 ]
Einhorn, Lawrence [2 ]
Bunn, Paul A. [1 ]
机构：
[1] Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80309 USA
[2] Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN USA
来源：
JCO PRECISION ONCOLOGY | 2025年 / 9卷
关键词：
D O I：
10.1200/PO-24-00536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
  • [42] Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
    van der Wekken, Anthonie J.
    Kok, Klaas
    Groen, Harry J. M.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2130 - S2132
  • [43] Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
    Hirai, Noriko
    Sasaki, Takaaki
    Okumura, Shunsuke
    Minami, Yoshinori
    Chiba, Shinichi
    Ohsaki, Yoshinobu
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers
    Yoshida, Ryohei
    Okumura, Shunsuke
    Sasaki, Takaaki
    Osaki, Yoshinobu
    CANCER RESEARCH, 2016, 76
  • [45] MYC Amplification as a Potential Mechanism of Primary Resistance to Crizonib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
    Rihawi, Karim
    Alfieri, Roberta
    Fiorentino, Michelangelo
    Fontana, Francesca
    Capizzi, Elisa
    Cavazzoni, Andrea
    Terracciano, Mario
    La Monica, Silvia
    Ferrarini, Alberto
    Buson, Genny
    Petronini, Pier Giorgio
    Ardizzoni, Andrea
    TRANSLATIONAL ONCOLOGY, 2019, 12 (01): : 116 - 121
  • [46] Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2016, 12 (07) : 945 - 961
  • [47] ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne, Florence
    Quere, Gilles
    Andrieu-Key, Sophie
    Descourt, Renaud
    Quintin-Roue, Isabelle
    Talagas, Matthieu
    Braekeleer, Marc De
    Marcorelles, Pascale
    Uguen, Arnaud
    LUNG CANCER, 2016, 91 : 67 - 69
  • [48] Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
    Zhang, Isabella
    Zaorsky, Nicholas G.
    Palmer, Joshua D.
    Mehra, Ranee
    Lu, Bo
    LANCET ONCOLOGY, 2015, 16 (13): : E510 - E521
  • [49] Crizotinib rechallenge reverses MET amplification-mediated resistance to ALK inhibitors in a patient with advanced ALK-rearranged non-small cell lung cancer: a case report
    Wang, Rixiang
    Chen, Weizhuang
    Jiao, Wenrui
    Ren, Feng
    Wu, Hongcheng
    Wu, Shibo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (08): : 6163 - 6167
  • [50] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
12345